Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jul;9(5):560-572.
doi: 10.1002/cpdd.807. Epub 2020 May 19.

Pharmacokinetics of Gepotidacin in Renal Impairment

Mohammad Hossain  1 , Courtney Tiffany  1 , Aparna Raychaudhuri  1   2 , Dung Nguyen  1 , Guoying Tai  1 , Harry Alcorn Jr  3 , Richard A Preston  4 , Thomas Marbury  5 , Etienne Dumont  1
Affiliations
Clinical Trial

Pharmacokinetics of Gepotidacin in Renal Impairment

Mohammad Hossain et al. Clin Pharmacol Drug Dev. 2020 Jul.

Abstract

Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. In this phase 1, nonrandomized, open-label, parallel-group, multicenter, multipart study, the pharmacokinetics, safety, and tolerability of a single intravenous (IV) dose of gepotidacin 750 mg over 2 hours were evaluated in subjects with normal renal function, in those with moderate and severe renal impairment, and in end-stage renal disease (ESRD) on and not on dialysis. Administration of IV gepotidacin 750 mg was safe and generally tolerated in the study subjects. Dosing in severe renal impairment with and without hemodialysis resulted in significant increases in plasma drug levels and decreases in clearance. The geometric mean elimination half-life (t½ ) was minimally impacted (range 9.45 to 11.5 hours) in all the renal-impairment groups relative to normal renal function. Regardless of renal function, urine gepotidacin concentrations remained considerably high over a 12-hour period. Saliva concentrations displayed a linear relationship with plasma concentrations. The t½ in saliva was not impacted in the moderate-impairment and ESRD subjects and was comparable to t½ in plasma. Over a 4-hour dialysis, approximately 6% of the gepotidacin dose was removed. Overall, subjects with severe renal impairment and ESRD with and without hemodialysis may require adjustment in dose or dosing frequency.

Trial registration: ClinicalTrials.gov NCT02729038.

Keywords: end-stage renal disease; gepotidacin; pharmacokinetics; physiologically based pharmacokinetic modeling; renal impairment; safety.

PubMed Disclaimer

Conflict of interest statement

M.H., C.T., A.R., D.N., G.T., and E.D. were employees of GSK and hold company stock. H.A., R.P., and T.M. were the study investigators funded by GSK during the conduct of the study. All authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors.

Figures

Figure 1
Figure 1
Relationship between gepotidacin clearance and renal function. CL indicates clearance; EGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease; R2, R2 (correlation coefficient).
Figure 2
Figure 2
Mean gepotidacin urine concentrations by renal function (semilogarithmic scale). Lower limit of quantification (LLOQ) = 1.00 μg/mL represented by dashed line; E coli MIC = 4 μg/mL, represented by solid line. All values below LLOQ were set to 0. Subjects with ESRD on hemodialysis received gepotidacin 750 mg starting 2 hours before initiation of the last hemodialysis (period 1; ESRD before hemodialysis) and starting 2 hours after completion of the last hemodialysis (period 2; ESRD after hemodialysis). ESRD indicates end‐stage renal disease; MIC, minimal inhibitory concentration.
Figure 3
Figure 3
Scatterplot of gepotidacin saliva and unbound plasma AUC0‐∞ by renal function (log‐log plot). Plasma parameters are presented as protein‐corrected values (67% protein correction factor): unbound plasma parameters = total plasma parameter × 0.67. Saliva parameters represent unbound drug parameters because saliva drug concentrations do not require correction for protein binding. AUC indicates area under the concentration‐time curve; ESRD, end‐stage renal disease.
Figure 4
Figure 4
Plot of gepotidacin total plasma, unbound plasma, and saliva concentrations in normal subjects and subjects with moderate renal impairment.
See this image and copyright information in PMC

References

    1. Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466(7309):935‐940. - PubMed
    1. Biedenback DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60:1918‐1923. - PMC - PubMed
    1. Ross JE, Scangarella‐Oman NE, Flamm RK, Jones RN. Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014;52(7):2629‐2632. - PMC - PubMed
    1. Negash K, Andonian C, Felgate C, et al. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica. 2016;46(8):683‐702. - PubMed
    1. Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. A phase I, randomized, double‐blinded, placebo‐ and moxifloxacin‐controlled, four‐period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12‐lead electrocardiogram in healthy volunteers. Antimicrob Agents Chemother. 61:e02385‐16. 10.1128/AAC.02385-16/bib> - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data